type here...

CATEGORIES

News and Views

LATEST

Editors Choice

The Subtle Signs of Brewing Violence May Be Seen, But Not Always

Pat Farrell PhD -
Editors Choice

HT World Correspondent and Medika Editor Gil Bashe Talks with the Medika50 Influencer Who Put Everything On the Line for Patients

Gil Bashe, Medika Life Editor -
Editors Choice

Artificial Intelligence and Mental Health

Michael Hunter, MD -
Editors Choice

Has Therapeutic Touch Lost Its Way in Medicine? Or Is It Lawsuits?

Pat Farrell PhD -
Diagnostics

Babson Diagnostics, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings

Medika Life -
Press Release

Achieve Life Sciences Announces Statistically Significant Smoking Cessation Results in Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Medika Life -
Editors Choice

If Agony and Numbness From Media War Coverage Generate Mental Aching, Why Watch?

Pat Farrell PhD -
For Doctors

The Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program Announces First Group of Physicians to be Trained

Medika Life -
Press Release

Cogitativo Joins the Veterans Health Administration to Address the Deferred Care Challenge Using AI-Enabled Solution

Medika Life -
Press Release

New National Survey of People Living with Bipolar I Disorder Provides Insights Into Disease-Related Challenges and the Treatment Journey

Medika Life -
1234...7Page 3 of 7

TRENDING

EDITORS CHOICE

Before Looking at the Results of the Paper on MDMA to Treat PTSD…

James Coyne -
So what really is the truth about MDMA and PTSD. Does this research published in Science hold up to scrutiny is is there a problem. Watch this space

The Healthcare Trail of Tears

Pat Farrell PhD -
Has the United States contributed to the plight of the Native peoples and has it been perpetuated by current administrations?

The MDMA-Assisted Therapy for PTSD Study. What You’ll Get Wrong

James Coyne -
Readers, including even experts, are falling for a hard sell job by venture capitalists who launder their funding of the study through a nonprofit foundation and seek not legalization

Treatment for Schizophrenia and Bipolar I Disorder Gets Vote of Support

Medika Life -
The Alkermes ALKS 3831 development program is part of our ongoing commitment to develop new therapeutic options for adults living with serious mental illness.

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

© Medika Life 2020 - 2022

Compliance

CORPORATE & MEDIA

Popular categories